Enhancer of zeste homolog 2 (EZH2), which is overexpressed in a wide range of tumors, contributes to ovarian cancer malignancy in several different ways. We aimed to illustrate the role of EZH2 in ovarian cancer cisplatin resistance and to identify possible underlying mechanisms of this role that may provide a rationale for targeting EZH2 in cancer treatment. Here, we present data indicating that EZH2 overexpression is associated with cisplatin resistance and intracellular platinum drug accumulation. Measurements of EZH2 in 84 ovarian cancer patients suggested that patients with high EZH2 levels tend to have poor responses to cisplatin. The EZH2 level progressively increased in cells receiving repeated cisplatin exposure. Downregulation of EZH2 not only sensitized cellular reactions to cisplatin and increased cellular platinum accumulation when cells were exposed to both cisplatin and BOD-IPY-Pt (a fluorescent cisplatin complex) but also protected copper transporter 1, a high-affinity copper transporter closely related to cisplatin resistance, from cisplatininduced proteasomal degradation. Overall, these findings identify a new mechanism that expands the unrecognized role of EZH2 in ovarian cancer cisplatin resistance.
bladder cancer and non-small-cell lung cancer. 5, 6 This evidence suggests that reduced platinum accumulation is an important mechanism of platinum resistance.
The enhancer of zest homolog 2 (EZH2) is the catalytic component of the polycomb repressive complex 2 (PRC2), which can transfer methyl groups to histone 3 on lysine 27 (H3K27Me3) by the SET domain to repress gene transcription through DNA methylation. 7 In normal biological processes, the expression of EZH2 is silenced after it fulfills its duty in embryonic development. However, the overexpression of EZH2 in cancer compared to normal tissue has brought this protein to the attention of oncologists. 8, 9 Previous studies investigating the basic genetic landscape of EZH2 in cancers and how it promotes malignancy revealed that EZH2 is involved in a wide range of cancer-associated processes. In ovarian cancer, mounting evidence suggests that EZH2 correlates with shortened overall survival in ovarian cancer patients, 10 induces the epigenetic repression of tumor-suppressor genes, 11 enhances the proliferation, migration, and invasion ability of ovarian cancer cells in vivo and in vitro, 12 participates in maintaining the ovarian cancer epithelial phenotype, and represents a new characteristic of the ovarian cancer stem cell-like population. 13 In this paper, we explored the relationship between EZH2 and cDDP resistance in ovarian cancer. This analysis was achieved by establishing the correlation between EZH2 and cDDP resistance in cellular models and patient tissue samples. In addition, we examined the effect of EZH2 on cellular platinum accumulation. Finally, we studied the reaction of copper transporter 1 (CTR1), a high-affinity copper influx transporter closely related to platinum resistance, to cDDP in ovarian cancer cells and analyzed how EZH2 is involved in the interaction between cDDP and CTR1. with a water wash. The slides were then rinsed in citrate (pH 6.0) for antigen retrieval through microwave irradiation followed by the procedures outlined in the Histostain SP Kit protocol. Anti-EZH2 antibody
| MATERIALS AND METHODS
(1:100; Cell Signaling Technology, USA) was applied at 4°C in a humidified atmosphere overnight. The bound antibody was detected using a DAB Kit (ZSGB-Bio). The images were documented using a fluorescence microscope (IX71; Olympus, Japan).
Two investigators blinded to patient information and sample data evaluated the EZH2 expression independently. Discrepancies were solved by discussion or by consulting a third pathologist. A semiquantitative scale was used to assess the immunostaining of EZH2 and CTR1. A staining score (0-9) was calculated by multiplying the staining intensity score (0, negative; 1, light yellow; 2, yellow; and 3, dark brown) with the positive proportion of cells (0, 0%; 1, <25%; 2, 25%-50%; 3, 50%-75%; 4, >75%). 
| Cell transfection
Lentiviral EZH2 specific shRNA (shEZH2) and a scrambled control shRNA (shNC) were synthesized by GenePharma (Suzhou, China).
The sequences were: shEZH2, 5 0 -GCAACACCCAACACTTATAAG-3 0 ;
and shNC, 5 0 -TTCTCCGAACGTGTCACGTTTC-3 0 . Small interfering RNAs specific for EZH2 and a scrambled control were synthesized by Genechem (Shanghai, China). The sequences were: siEZH2, 5 0 -TTGCCTTCTCACCAGCTGC-3 0 ; and siNC, 5 0 -TTCTCCGAACGTG TCACGT-3 0 . The EZH2 overexpression plasmid was constructed in our laboratory as previously described (GV166-EZH2 plasmid). 9 Stable transfection of the EZH2 knockdown lentivirus and EZH2 overexpression plasmid was undertaken as previously described. 9 The siRNA transient transfections were carried out using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA).
| Real-time PCR
RNA extraction and real-time PCR were carried out as previously described. 15 The sequences of the primers were: EZH2 forward, 
| Western blot analysis
Cell lysate preparation and Western blotting were undertaken as previously described. 16 The primary antibodies used were EZH2
(1:1000; Cell Signaling Technology), CTR1 (1:500; Santa Cruz Tech- 
| Cytotoxicity assays
Cells (4000 per well) were seeded in 96-well plates and treated with a range of cDDP (0-32 lmol/L) for 72 hours. Viability was assayed by MTS (Sigma) according the manufacturer's instruction.
| Colony formation assay
Cells (1000 per well) were seeded and incubated with different concentrations of cDDP (0-8 lmol/L) for 24 hours and change to drugfree media until visible colonies appeared. The colonies were fixed with 4% formaldehyde, stained with crystal violet, counted, and photographed. Clusters of more than 50 cells were considered a colony.
| Determination of cellular platinum accumulation, uptake, and efflux
Cell pellets were harvested after 12 hours of exposure to 30 lmol/L cDDP. The pellets were divided into halves, one for protein determination using a BCA Protein Assay Reagent Kit (Bio-Rad), and the other was kept frozen until submission for flame atomic absorption spectroscopy (FAAS) analysis as previously described. 17 To examine the influx rate, cells were exposed to 500 lmol/L cDDP and harvested at different time points. To examine cDDP efflux, cells were exposed to 500 lmol/L cDDP for 10 minutes (time 0), washed with cold PBS and kept in drug-free medium for 10, 20, and 30 minutes.
Cells collected at each time point were processed as described above. 
| Immunofluorescence

| Statistical analysis
Student's t-test and the Mann-Whitney test were performed with Prism 6.0 software (GraphPad Software, San Diego, CA, USA). Pvalues <.05 were considered statistically significant.
| RESULTS
| Enhancer of zeste homolog 2 is associated with cDDP resistance in ovarian cancer
To verify the relationship between EZH2 and cDDP resistance, we first compared EZH2 expression in chemosensitive vs chemoresistant tumors. As shown in Figure 1 (A), the tissue microarray and immunohistochemical assays revealed that EZH2 staining in the chemoresistant group was much stronger than in the chemosensitive group. As CTR1 was a prognostic marker for ovarian cancer chemotherapy response, as assessed in our previous meta-analysis, 18 we also included the measurement of CTR1 using our own cohort to validate this previous conclusion.
As expected, the chemosensitive group showed stronger CTR1 staining.
We undertook a correlation analysis between EZH2 and CTR1 levels but we did not find any evidence of correlation ( Figure S1 ; Pearson R = À.1301, P = .326). Next, we generated two cDDP-resistant cell sublines, A2780C12 and ES2C12, by exposing A2780 and ES2 parental cells to 12 cycles of cDDP treatment, respectively ( Figure 1B ). We observed a progressively increased expression of EZH2 and its substrate
H3K27Me3 in both cell lines during cDDP resistance induction (Figure 1C) . To verify the contribution of EZH2 to cDDP resistance in ovarian cancer cells, A2780 and ES2 were stably transfected with EZH2 inhibition plasmid shEZH2, ES2 was stably transfected with EZH2 overexpression plasmid ( Figure 1D,E) . The downregulation of EZH2 dramatically increased the sensitivity of A2780 and ES2 cells to cDDP, whereas overexpression of EZH2 contributed to cDDP resistance ( Figure 1F ).
| Enhancer of zeste homolog 2 affects intracellular platinum accumulation
In a previous study, we observed increased cDDP accumulation accompanied by a decrease in EZH2 in mouse s.c. xenografts after cDDP and let-7e agomir combination treatment. 19 To determine whether EZH2 affects platinum accumulation in ovarian cancer cells,
we analyzed the platinum content of cells with different EZH2 levels. We found that platinum content was significantly higher in the EZH2 downregulated cells compared to the controls in both the A2780 and ES2 cell lines (Figure 2A ). Moreover, according to the influx and efflux curves, EZH2 depletion seemed to increase cellular platinum uptake rather than interfere with platinum efflux (Figure 2B,C) . Furthermore, we used a fluorescence-modified cDDP analog, BODIPY-Pt, ( Figure 2D Bars represent mean AE SD (n = 3). *P < .05, **P < .01, ***P < .001, ***P < .0001, Student's t-test. ShNC, scrambled control Bars represent mean AE SD (n = 3). *P < .05, **P < .01, ****P < .0001, Student's t-test. ShEZH2, EZH2 shRNA; ShNC, scrambled control intensity in the siEZH2 transfected cells (Figures 3A,S2) . Previous studies reported that expression of the copper transporter CTR1 is closely related to cellular and tissue platinum accumulation and clinical outcomes. 18, [20] [21] [22] In this case, we investigated cellular CTR1 expression and localization when treated with BODIPY-Pt. Cellular CTR1 expression ( Figure 3A , red) underwent a minor decrease shortly after exposure to BODIPY-Pt and then remained steady ( Figures 3A,S2 ).
BODIPY-Pt ( Figure 3A , green) had an early diffusion, and none entered the nucleus. A fraction of BODIPY-Pt remained at the surface of the cell during all time points, mirroring the CTR1 signal pattern. The Pearson correlation coefficients of the two signals were significant and consistent (Table S1 ). Given the involvement of EZH2 in cellular platinum accumulation and the engagement of CTR1 in transporting platinum complexes, we hypothesized that EZH2 might also play a role in the interaction between CTR1 and cDDP. Cellular CTR1 expression went through a time-dependent decrease when exposed to cDDP (Figure 3B ) that was independent of drug concentration ( Figure S2 ). Cisplatin caused greater CTR1 degradation in our previously generated cDDP-resistant cell line ACP when compared to A2780 ( Figure 3C ). 23 Next, we compared the response of CTR1 to cDDP when regulating EZH2 expression. We found that, after 12 hours of cDDP treatment, CTR1 expression decreased in the control cells but remained the same in EZH2 knockdown cells ( Figure 3D ). Similar results were seen when EZH2 was inhibited by GSK126 and DZNEP ( Figure 3E ).
| Enhancer of zeste homolog 2 accelerates cDDP-induced proteasomal CTR1 degradation
To explore further, we asked whether EZH2 has any influence on CTR1 protein stability. The half-life of CTR1 in cells transfected with shEZH2 and controls is similar ( Figure 4A ). Next, the cells were exposed to cDDP after cellular protein synthesis inhibition by CHX.
EZH2 depletion protected CTR1 from cDDP-induced degradation ( Figures 4B,S3 ). To confirm these results, we incubated the cells with MG132 to block the proteasomal degradation pathway mediated by ubiquitination and then measured the mono-and poly-ubiquitination level of CTR1 ( Figure 4C ). The mono-and poly-ubiquitinated CTR1 levels were significantly higher in controls than in cells transfected with shEZH2.
| DISCUSSION
In this study, we first established a significant association between EZH2 and cDDP resistance in the development of cellular cDDPresistant models and the analysis of patient tissue samples. Then we examined the effect of EZH2 on cellular platinum accumulation directly by measuring cellular platinum content and indirectly by mimicking cDDP uptake with a fluorescence-conjugated platinum BODIPY-Pt; both methods showed that high EZH2 decreased cellular platinum uptake. Next, we found that EZH2 was somehow involved in the cDDP-CTR1 interaction and high EZH2 accelerated cDDP-induced proteasomal CTR1 degradation. These findings suggested that EZH2 plays a crucial role in the development of cDDP resistance.
Although it has been reported that the loss of EZH2 induces resistance to multiple drugs in acute myeloid leukemia, 24 Several transporters are involved in platinum transportation including the copper transporting system and the organic cation transporters. We evaluated the prognostic implication of CTR1, CTR2, ATP7A, and ATP7B on ovarian cancer prognosis in our previous meta-analysis. 18 We only found correlation of clinical significance between chemotherapeutic resistance and CTR1 but not CTR2, ATP7A, or ATP7B. Additionally, we measured cellular ATP7A, ATP7B, and CTR2 expression after EZH2 modification by Western blot analysis, no significant changes were observed ( Figure S4 ).
Copper transporter 1 has gained much attention and raised furious debates ever since the discovery of its interaction with cDDP in yeast and mammals. 30, 31 Based on current knowledge, the general role of CTR1, which was once proposed as a major pathway for cDDP uptake, must be re-evaluated due to various controversial results. 4, [32] [33] [34] [35] As the cellular expression level of CTR1 is significantly higher in sensitive cells than in resistant cells with matching cDDP uptake differences 32, 34 35 we observed an overall CTR1 decrease at a much slower rate after cDDP treatment. Similar to the observation by Safaei et al, 39 the cDDP-induced CTR1 decrease was accompanied by an increase in CTR1 ubiquitination, a symbol of proteasomal degradation. The controversial results between these studies were probably due to variances in tumor type, detection methods, and reagent choice.
Based on our observation that depletion of EZH2 slowed cDDPinduced CTR1 degradation, we initially hypothesized that EZH2 might influence key enzymes regulating CTR1 degradation, as shown in Figure 5 . In our attempt to identify key proteins contributing to CTR1 degradation, we pulled down CTR1-associated proteins by immunoprecipitation after cellular EZH2 modification. We submitted those CTR1-associated proteins for mass spectrometry analysis in order to find ubiquitin-associated proteins, which would likely be the targets of EZH2. However, like Tsai et al, 40 the E3 ligase of CTR1
was still not determined due to a noisy background created by cellular reactions to cDDP. Although we failed to tease out the CTR1-specific E3 ligase in cDDP-treated samples, we identified a series of depleted pathways for protein synthesis and metabolism (data not shown). A group of ribosome-associated proteins encoded by ribosome-related genes, once proposed to be involved in acquired cDDP resistance, 41 were depleted with EZH2 downregulation. It is still unclear how EZH2 contributes to cDDP-induced CTR1 degradation and whether the ribosome-related genes influenced by EZH2 play a role in acquired cDDP resistance. Although it is well recognized that EZH2 mainly located in the nuclei, several lines of evidence show that cytoplasmic EZH2 retains its methyl transfer activity and is involved in cellular skeleton movement, ubiquitinmediated protein degradation, cytoskeleton formation, cell adhesion, and migration. [42] [43] [44] We examined the EZH2 location using immunofluorescence in several cell lines, including cDDP-sensitive/ resistant cell lines and those with EZH2 depletion. We observed both nuclear and cytoplasmic EZH2 expression while EZH2 mainly remained in the nuclei. Based on previous findings, it is plausible that cytoplasmic EZH2 modulated CTR1 degradation through its methyl transfer activity.
In addition to mediating cellular platinum uptake, EZH2 participated in malignant biological behavior of ovarian cancer through regulating BRCA1 expression 15 and enhanced cDDP resistance through promoting DNA replication, pyrimidine metabolism, cell cycle, and cell proliferation. 25, 45 Therefore, alteration of EZH2 regulating miRNAs and lncRNAs were also engaged in cDDP resistance. 46 All in all, the results of the current study provide new details regarding how EZH2 promotes platinum resistance by decreasing cellular platinum accumulation, which adds a new mechanism to the bulk repertoire; this mechanism can be applied when interpreting how EZH2 promotes malignancy and, more specifically, when determining the F I G U R E 5 Proposed model for enhancer of zeste homolog 2 (EZH2) mediating cisplatin (cDDP)-induced copper transporter 1 (CTR1) degradation. Atox1, antioxidant 1 copper chaperone; ER, endoplasmic reticulum; E2, ubiquitin-conjugating enzyme; E3, ubiquitin ligase; GSH, Glutathione; GSX, glutathione S-conjugate; Pt, platinum; Ub, Ubiquitin unrecognized function of EZH2 that contributes to ovarian cancer platinum resistance.
